Mercedes Porosnicu

7PUBLICATIONS
30CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 22, 2024
Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer.

Kimberly M Burcher, Chance H Bloomer, Elena Gavrila

|Sep 05, 2023
Exceptional response to cetuximab monotherapy after failure of immunotherapy with a checkpoint inhibitor in a patient with metastatic head and neck squamous cell cancer: case report and review of the literature.

Chance H Bloomer, Elena Gavrila, Kimberly M Burcher

|May 18, 2023
Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer.

Ryan T Hughes, Rediet R Gebeyehu, John Mason Kalada

|Dec 01, 2022
Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Charu Aggarwal, Nabil F Saba, Alain Algazi

|Oct 31, 2022
Serendipitous synergism - an exceptional response to treatment with pembrolizumab in the course of a natural immunovirotherapy: a case report and review of the literature.

Lara M Khoury, Kimberly M Burcher, Ronald T Ng

|Jun 14, 2022
Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors.

Mercedes Porosnicu, Anne-Marie Quinson, Kate Crossley

Pageof 2

Frequent Collaborators

2 joint publications

Ryan T Hughes

2 joint publications

Thomas W Lycan

2 joint publications

Kimberly M Burcher

2 joint publications

Chance H Bloomer